4.8 Article

Differential Requirements for eIF4E Dose in Normal Development and Cancer

期刊

CELL
卷 162, 期 1, 页码 59-71

出版社

CELL PRESS
DOI: 10.1016/j.cell.2015.05.049

关键词

-

资金

  1. NIH Director's New Innovator Award [7DP2OD00850902]
  2. NIH [R01CA140456, R01CA154916, R01CA184624, 1F32CA189696, P30CA82103]
  3. Alfred P. Sloan Research Fellowship
  4. Mallinckrodt Foundation Award
  5. Pew Scholars Award
  6. American Cancer Society grant [PF-14-212-01-RMC]
  7. Life Science Research Foundation Postdoctoral Fellowship
  8. Onyx Oncology Innovation Alliance Award

向作者/读者索取更多资源

eIF4E, the major cap- binding protein, has long been considered limiting for translating the mammalian genome. However, the eIF4E dose requirement at an organismal level remains unexplored. By generating an Eif4e haploinsufficient mouse, we found that a 50% reduction in eIF4E expression, while compatible with normal development and global protein synthesis, significantly impeded cellular transformation. Genome- wide translational profiling uncovered a translational program induced by oncogenic transformation and revealed a critical role for the dose of eIF4E, specifically in translating a network of mRNAs enriched for a unique 5' UTR signature. In particular, we demonstrate that the dose of eIF4E is essential for translating mRNAs that regulate reactive oxygen species, fueling transformation and cancer cell survival in vivo. Our findings indicate eIF4E is maintained at levels in excess for normal development that are hijacked by cancer cells to drive a translational program supporting tumorigenesis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据